What You Should Know About Vaccine Safety National Immunization Conference April 1, 2009 Beth Hibbs, RN, MPH Tanya Johnson, MPH Nancy Levine, RN, PhD Immunization.

Slides:



Advertisements
Similar presentations
The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.
Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.
Julianne Gee, MPH Immunization Safety Office
VACCINE SAFETY: 101 Pandemic Influenza Vaccine Safety Conference Atlanta, Georgia August 21, 2008.
IMMUNIZATION Immunization??? Reduce mortality and morbidity of mathernal and baby.
PROTECTING BABIES THROUGH IMMUNIZATION SAFE AND HEALTHY BABIES.
Tom Shimabukuro, MD, MPH, MBA Immunization Safety Office Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious.
1 VAERS Reporting During a Large Scale Vaccination Clinic in Chicago Lessons Learned Chicago Department of Public Health Immunization Program Lorraine.
Tom Shimabukuro, MD, MPH, MBA Immunization Safety Office Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious.
Monitoring Safety of Rotavirus Vaccines David Martin, MD, MPH CBER Office of Biostatistics and Epidemiology, FDA For presentation at the Vaccines and Related.
Immunizations Donna Hills APN EdD Ball & Bindler.
IMMUNIZATIONS HEALTHROOM ASSISTANT TRAINING Cheri Dotson, RN, BSN, MA
Module 6 Inactivated poliovirus vaccine AEFI monitoring Training for Inactivated Poliovirus Vaccine (IPV) introduction.
Medicinal Chemistry 401: Immunizing Agents 2007 Instructor: Valerie Daggett, Date TimeLecturerTopicReadingsSlides 5/48:30 amDaggett.
Vaccine Education Module: Vaccines Updated: April 2013.
ELIZABETH WILLIAMS, MD FELLOW IN VACCINOLOGY AND VACCINE SAFETY VANDERBILT UNIVERSITY AUGUST 30 TH, 2012 Thimerosal and Vaccine Safety.
Why Vaccines Are Important for Children
Health Care Personnel Influenza Vaccination [ORGANIZATION NAME] [ORGANIZATION LOGO]
Case Study: Jennifer and James Amy B. Middleman, MD, MSEd, MPH Assistant Professor, Department of Pediatrics, Adolescent Medicine Section, Baylor College.
Vaccine Safety Concerns  Past of vaccines  Now most parents have never seen a case of diphtheria, measles, or other once- common diseases.  They therefore.
Childhood Immunization Update for WIC and Clerical Personnel Presented by: Date:
Measles and Measles Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases Centers.
Vaccine Safety Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised.
Jeff Neccuzi, Director Division of Immunization Services WV Bureau for Public Health.
Adult Immunization 2010 Tetanus, Diphtheria and Pertussis Segment This material is in the public domain This information is valid as of May 25, 2010.
Immunizations: 101 The Basics of Vaccine Administration
EMPLOYEE INFLUENZA VACCINATON. Influenza Vaccination (Your institution) is committed to keep both its employees and patients safe (Your institution) recognizes.
The National Vaccine Plan Process - Update October 22, 2007 Raymond A. Strikas, MD National Vaccine Program Office Department of Health and Human Services.
Introduction to US Health Care
Viral Hepatitis - Historical Perspective A “Infectious” “Serum” Viral hepatitis Entericallytransmitted Parenterallytransmitted F, G, ? other E NANB BD.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 68 Childhood Immunization.
Preparing for Vaccine Administration: Warnings, Precautions and Contraindications Ruth Carrico PhD RN FSHEA CIC Associate Professor Division of Infectious.
Respond Detect Report Investigate Adverse Events Following Immunization Dr S.M.Zahraei Center for Disease Control Ministry of Health and Medical Education.
Economic Evaluation of Routine Childhood Immunization with DTaP, Hib, IPV, MMR and HepB Vaccines in the United States, 2001 Fangjun Zhou Health Services.
5th Annual Advocacy Project: ImmuneWise Section on Medical Students, Residents, and Fellowship Trainees
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
10/27/2015Immunization schedule1. Immunization M. Emadoleslami MD.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
(Slide 1 of 22) Response to the National Vaccine Advisory Committee Recommendations on the Immunization Safety Office Scientific Agenda Frank DeStefano,
Expanded program of Immunization (EPI) Introduction The Expanded Program on Immunization (EPI) was established in 1974 depending on the success of the.
Component 1: Introduction to Health Care and Public Health in the U.S. 1.1: Unit 2: Health Care Settings 1.2 a: Overview and the Organization of Federal.
Treat with confidence. Trusted answers from the American Academy of Pediatrics. The 2015 Childhood Immunization Schedule H. Cody Meissner, MD, FAAP Floating.
Immunization Safety Office Nuts and Bolts a Basic Course VACCINE SAFETY: nd National Immunization Conference Atlanta, Georgia March 17, 2008.
PRESENTED BY : 1. TAHSIN TASNIM ATASHI 2. SAMIHA ASHREEN 3. ZAREEN NAWAR.
National Immunization Conference March 30, 2011 Elaine R. Miller, RN, MPH Beth Hibbs, RN, MPH What Healthcare Providers Need to Know about the Vaccine.
Module 7 Communicating with parents, caregivers and health personnel about IPV and multiple injections Training for Inactivated Poliovirus Vaccine (IPV)
1 Review of the Vaccine Adverse Event Reporting System (VAERS) Beth Hibbs RN, MPH; Elaine Miller RN, MPH Immunization Safety Office (ISO) Division of Healthcare.
Module 6 Monitoring Events Supposedly Attributable to Vaccination or Immunization (ESAVIs) Training for Inactivated Poliovirus Vaccine (IPV) introduction.
Job Corps Webinar: Immunizations John Kulig MD MPH Lead Medical Specialist September 29 & 30, 2010.
Principles of Vaccination Epidemiology and Prevention of Vaccine- Preventable Diseases Source: Centers for Disease Control and Prevention.
NEW TECHNOLOGIES IN VACCINES. Vaccination – is the introduction into the body of a weakened, killed or piece of a disease-causing agent to prevent disease.
National Vaccine Injury Compensation Program HRSA The National Vaccine Injury Compensation Program (VICP): What’s New? National Immunization Conference.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Childhood Immunization.
Mark V. Francesconi Vaccine Manager, Immunization Program Rhode Island Department of Health.
National Immunization Conference April 19, 2010
General guide for assessing immunizations among refugees
World Health Organization
CD-JEV AEFI monitoring
World Health Organization
Quadrivalent Human Papillomavirus Vaccine (HPV4) Adverse Events
World Health Organization
Module 6 Rotavirus vaccine AEFI monitoring
Chapter 27 Pediatrics.
World Health Organization
How Vaccines work.
Immunologic Medications
Module 6 Rotavirus vaccine AEFI monitoring
Module 6 Rotavirus vaccine AEFI monitoring
Module 6 Rotavirus vaccine AEFI monitoring
Presentation transcript:

What You Should Know About Vaccine Safety National Immunization Conference April 1, 2009 Beth Hibbs, RN, MPH Tanya Johnson, MPH Nancy Levine, RN, PhD Immunization Safety Office Division of Healthcare Quality Promotion Centers for Disease Control and Prevention

Objectives Discuss roles of federal agencies in pre- and post-licensure vaccine safety Describe CDC’s role in vaccine safety Outline the clinician’s role in vaccine safety Present selected vaccine safety concerns

Historical Perspective

Federal Agencies NCIRD ISO Centers for Disease Control and Prevention (CDC) Health Resources and Services Administration (HRSA) Food and Drug Administration (FDA) National Institutes of Health (NIH) Department of Health and Human Services (DHHS) National Vaccine Program Office (NVPO)

CDC and Vaccine Safety Coordinating Center for Infectious Diseases (CCID) Centers for Disease Control and Prevention Advisory Committee on Immunization Practice National Center for Immunization and Respiratory Diseases National Center for Preparedness, Detection, and Control of Infectious Diseases Division of Healthcare Quality Promotion Immunization Safety Office

Vaccine Injury Compensation Program Health Resources and Services Administration (HRSA) Created in 1988, located in HRSA Funded by excise tax on manufacturers Covers childhood vaccines only No fault alternative for resolving vaccine injury claims Involves 3 federal agencies: –Department of Health and Human Services –Department of Justice –US Court of Federal Claims

Pre-Licensure Testing Animal tests - Test immune response. Assure no major side effects. Human clinical trials –Phase I gross toxicity –Phase II safety effectiveness –Phase III safety and effectiveness Manufacturer applies for two licenses FDA advisory committee reviews clinical data and makes recommendation

Post-Licensure Vaccine Safety US Food and Drug Administration (FDA) After approval, samples of each lot of a vaccine must be submitted to the FDA before it can be released for use. Tested for bacterial and fungal sterility, general safety, potency, and purity

Post-Licensure Vaccine Safety Advisory Committee on Immunization Practices (ACIP) Advises HHS Secretary and CDC Director about reducing incidence of vaccine-preventable diseases and increasing vaccine safety Advises on the safety and efficacy of vaccines in the civilian population and makes written recommendations on: –US-licensed vaccines –Other agents related to controlling vaccine- preventable diseases such as immune globulin preparations, antimicrobial therapy and chemoprophylaxis

11 YearACIP Recommendation for United States 1997Use 5-dose of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) schedule, instead of whole cell pertussis vaccine (DTP) 1997Use Inactivated Poliovirus Vaccine (IPV) for first 2 doses of polio vaccination, instead of oral poliovirus vaccine (OPV) 1999Use IPV for all 4 doses instead of OPV 1999Withdraw recommendation for rotavirus vaccine (Rotashield ® ) use 2008Remove preference for administering combination measles, mumps, rubella and varicella (MMRV) vaccine over separate injections MMR and varicella vaccines Key ACIP Decisions on Vaccine Safety

ISO ’ s Role in Post-licensure Vaccine Safety Surveillance  Monitors the safety of all vaccines licensed for use in the United States Research  Investigates adverse events and identifies risk factors for adverse events Cross-cutting Activities  Develops standardized terminology, new research techniques and guidelines for enhancing clinical practice in vaccine safety Communication  Communicates with partners and the public about adverse events associated with immunization

Step One: detecting a potential vaccine safety problem Vaccine Adverse Event Reporting System (VAERS) – National passive surveillance system – Co-administered by CDC and FDA – Receives ~30,000 reports per year – Creates database of adverse events Clinical review of VAERS reports – CDC and FDA staff – Clinical Immunization Safety Assessment (CISA) Network Conducting near real-time surveillance for specified adverse events – Vaccine Safety Datalink (VSD) Project ISO Surveillance

VAERS Limitations Reporting biases Statistical limitations Additional studies required to confirm signals Can not determine vaccine causality: An adverse event following immunization does not mean the vaccine caused the event

ISO Research and Investigation Step Two: testing hypotheses through research Vaccine Safety Datalink (VSD) Project – Collaboration with eight managed care organizations – Large linked databases on ~3% of US population – Provides information on health outcomes and vaccine histories CISA – Network of six academic centers – Conducts individual-level clinical studies – Identifies risk factors associated with developing AEFI Vaccine Analytic Unit (VAU) – CDC-DoD-FDA collaboration initiated to address safety of anthrax vaccination program – Military database on ~7 million people – Great potential to contribute to understanding of safety of other vaccines

ISO Cross-cutting Activities Step Three: standardizing terminology, creating new research techniques and enhancing clinical practice in vaccine safety Creating a common “language” – Brighton Collaboration –International scope – 1800 participants in 94 countries –Standardizes case definitions and guidelines for AEFI –Enhances ability to compare pre and post-licensure studies Developing newer, faster research methods –VSD: Rapid Cycle Analysis Helping clinicians assess and manage AEFI –CISA: Algorithm for health care providers to use in managing individuals with immediate hypersensitivity reactions following vaccination

ISO Communication, Collaboration and Education Step Four: translating vaccine safety surveillance and research for partners, providers and the public Journal articles Web site Educational materials: VAERS brochure Presentations at national conferences Media briefings Conference calls Technical assistance

Role of the Clinician in Vaccine Safety Assure proper vaccine storage and handling Screen for contraindications/ precautions Communicate vaccine risks/benefits Proper administration Manage possible vaccine reactions Document and report vaccine adverse events

Storage and Handling of Vaccines Proper condition on arrival Storage (refrigerate, freeze, light-protected) Shelf life (18m - 3yrs) Reconstitution (shaking, dilution) Shelf life after reconstitution (8 hrs - until outdated) Rotate stock so shortest dated material is used first Pre-filling syringes-not recommended

Screen for Contraindications/ Precautions Contraindications –conditions that increase the risk of serious adverse events Precautions –majority are temporary –vaccine can be given later Package inserts for each vaccine CDC General Recommendations on Immunization – ml/rr5515a1.htm Immunization Action Coalition Screening questionnaires – –

SPECIAL POPULATIONS History of severe allergic reaction People with moderate or severe illness Pregnant women Recent blood product recipients

When is it safe to immunize? Mild illness Disease exposure Antibiotic therapy Otis media Diarrhea Breast feeding Premature birth Most allergies Family history of vaccine reaction

Vaccine Administration Wash hands, gloves not required Equipment: needle length and gauge 5 rights: administer the correct –patient –vaccine –dose –route –time

Communicate Vaccine Information Statements Public Health law requires them to be provided to parents at each visit Contains Vaccine Safety information –VAERS –Vaccine Injury Compensation Referral information fault.htm

Vaccine Reactions Local Reactions Systemic Reactions Allergic Reactions Emotional

Vaccine Reactions: What You Can Do React to needs –Physical Immediate e.g. Anaphalaxsis, Syncope Delayed – e.g. fever, injection site reactions, other rare events –Emotional Refer as needed –Specialists –Information Reassure Report Follow up

Reporting Adverse Events to VAERS 3 ways to report Online: Secure website Fax: Mail: VAERS, P.O. Box 1100, Rockville, MD, Download form at

Vaccine Safety: Current Issues Concerns about Autism Safety of human papillomavirus (HPV) vaccine Vaccine Ingredients Vaccine Scheduling Simultaneous Vaccination Combination Vaccines Trust

Concerns about Autism Scientific evidence does not support a casual link between vaccines and autism Omnibus Autism Proceedings Concerns among parents and the public persist

HPV Vaccine Safety Human papillomavirus (HPV) vaccine protects against the types of HPV that most commonly cause cervical cancer and genital warts, and is recommended for adolescent girls and young women Media attention on the safety of the HPV vaccine has focused on the adverse events reported following vaccination – 94% of reports non-serious Fainting, pain at the injection site, headache, nausea, fever – 6% of reports serious Guillain-Barré Syndrome (GBS), blood clots, death All serious reports have been carefully analyzed. Experts have not found a common medical pattern to the reports of serious adverse events reported for the HPV vaccine that would suggest that they were caused by the vaccine.

Concerns about Ingredients in Vaccines Thimerosal – a mercury based preservative to prevent contamination Aluminum – used to enhance the immune system response Formaldehyde – used to inactivate bacteria and viruses

Vaccine Schedule & Combination Vaccines Concerns have been raised about: – The increasing number of recommended vaccines – Simultaneous vaccination Protects against several diseases in one visit Ensures children are less likely to fall behind schedule No evidence that giving multiple vaccines at the same time is harmful – Combination vaccines Reduce discomfort and costs

HHS Vaccine Safety Resources 800-CDC-INFO ( ) CDC Immunization Safety Office (ISO) Report Vaccine Adverse Events (VAERS) Vaccine Injury Compensation Program (VICP) US Food and Drug Administration (FDA)

Questions Thank you!